González-Treviño JL, García-Guerrero J, Villarreal-Mendez G, Cantú ROG

Language: Spanish
References: 19
Page: 75-78
PDF size: 77.83 Kb.

ABSTRACT

Pterygium is a fibrovascular proliferation originated in the conjunctive; the principal treatment is surgical, but the injury with much frequency recurs. Because of the antiangiogenic effect, bevacizumab was used in the present clinical essay to determine the effect in the stratification of pterygiums. During 2007, 26 eyes with pterygium with clinical progression were studied. 6.5 mg of bevacizumaban were injected in the body of the pterygium. A control group was considered for the statistical. The clinical aspect of the fibrovascular tissue was analyzed and compared a week and three weeks after the application. The procedure was performed under topic anesthesia. From 26 infiltrated eyes, 23 respond having changed their progressive stadium to stationary (rate of success of 88.46%). The tables of contingency demonstrated a statistically significant improvement in the values of the group treatment, confirming the raised hypothesis. The present study is the first one described in the literature that evaluated and documented the capacity of the monoclonal antibody to modify the clinical stadium of the pterygium.

REFERENCES

1. Coroneo MT, Di Girolamo N, Wakefield D. The Pathogenesis of Pterygia. Curr Opin Ophthalmol 1999; 10:282-8.

2. Lawrence WH. The treatment of pterygium. Surv Ophthalmol 2002; 30: 312.

3. Rosenthal JW. Chronology of pterygium therapy. Am J Ophthalmol 1953; 36:1016.

4. Peckar CO. The aethiology and histopathogenesis of pterygium. A review of the literature and a hypothesis. Doc Ophthalmol 1972; 31:141-57.

5. Buratto L, Phillips R, Carito G. Pterygium Surgery. Slack Inc. 2000.

6. De La Luz-Osnaya JC, Dewit-Carter GC, Sandra-Sarmina J. Frecuencia de recidiva en la resección quirúrgica de pterigión con aplicación tópica de mitomicina C vs. betaterapia, utilizando la técnica de esclerótica desnuda. Rev Mex Oftalmol 2000: 74(2):59-62.

7. Hernández-García G. Resección de pterigión: Experiencia en el Hospital Militar Regional de Acapulco, Gro. Rev Sanid Milit Mex 2004; 58(5):382-4.

8. Ibáñez-Hernández MA, Ramos-Espinoza K. Cirugía de pterigión: membrana amniótica vs. autoinjerto de conjuntiva. Rev Mex Oftalmol 2006; 80(1):9-11.

9. Gordon MS, Cunningham D. Managing Patients Treated with Bevacizumab Combination Therapy. Oncology 2005; 3(69):25-33.

10. Emmanouilides C, Pegran M, Robinson R, Hecht R, Isacoff W. Anti-VEGF antibody bevacizumab (AvastinÓ) with 5FU/LV as third line treatment for colorectal cancer. Tech Coloproctol 2004; 8:50-2.

11. Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R y cols. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132(3 Supl):277S-289S.

12. Senan S, Smit E. Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy. Oncologist 2007; 12:465-477.

13. Tsakonas G, Kosmas C. Integration of novel targeted therapies into the systemic treatment of breast cancer-a review. J BUON 2007;12(3):319-27.

14. Kelkar AS, Kelkar SB, Kelkar JA, Nagpal M, Patil SP. The use of intravitreal bevacizumab in neovascular glaucoma: a case report. Bull Soc Belge Ophtalmol 2007; (303):43-5.

15. Barros LE, Belfort-Jr R. The effects of the subconjunctival injection of bevacizumab (AvastinÓ) on angiogenesis in the rat cornea. An Acad Bras Cienc 2007; 79(3):389-94.

16. Höfling-Lima AL, Belfort-Jr R, Freitas D, Farah ME. Intrastromal Injection of Bevacizumab (AvastinÓ) for Treatment of Corneal Neovascularization. American Academy of Ophthalmology Annual Meeting, Las Vegas, Nov. 2006.

17. Castro MR, Lutz D, Edelman JL. Effect of COX on VEGFinduced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res; 79:275-85.

18. Hosseini H, Nejabat MA. Potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses 2007; 68:799–801.

19. Manzano R, Peyman G, Khan P, Carvounis P, Kivilcim M y cols. Inhibition of experimental corneal neovascularization by bevacizumab (AVASTIN). Br J Ophthalmol 2006. http://bjo.bmj.com/cgi/content/abstract/bjo.2006.107912v.